Abstract 210P
Background
Vascularization is known to be linked to tumour growth. We explored the potential of automated lung tumour vascularity assessment as risk factor for landmark survival.
Methods
131 CT scans from the NSCLC Radiogenomics dataset were evaluated. All patients underwent surgery, with or without other therapies. Primary lung tumour (PLT) is segmented by a radiologist. Vessels segmentation (arteries and veins) is performed by an in-house deep learning segmentation model. Vascularity features extracted for the PLT include: amount of blood vessel connections, % of the tumour surface connected to vessels (%area), and basic statistics on the surface area of the connections. A generalized linear model (GLM) to predict landmark survival was trained with these features, tumour volume, and clinical factors. Stepwise feature reduction was performed to arrive to the final model. We present the odds ratio (OR) as well as a combined risk score for the remaining independent predictors.
Results
Landmark survival was reached for 86/131 (66%) patients. GLM analysis showed 4 independent risk factors related to landmark survival: %area (OR= 1.69 for >2.5%), age (OR=1.57 for >70 years), gender (OR=2.10 for male) and radiation therapy (OR=1.51 for yes). Smoking status and tumor volume were not retained in the final model. We also showed that risk of dying before landmark survival increased with increased number risk factors (0%, 18%, 40%, 48% and 100% for 0, 1, 2, 3, 4 risk factors, respectively).
Conclusions
Lung tumour vascularity is an independent risk factor for landmark survival. We showed an approach were it can be used as additional prognostic factor to inform clinical decision making and therapy planning.
Clinical trial identification
Editorial acknowledgement
Fabio Bottari, PhD, of Radiomics for providing medical writing support in accordance with Good Publication Practice ( GPP 2022) guidelines.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
F. Blistein, F. Belmans, S. Goffart, L. Libert, R. Narasimhan, A. Corsi: Financial Interests, Personal, Full or part-time Employment: Radiomics. W. Vos: Financial Interests, Personal, Leadership Role: Radiomics. M. Occhipinti: Financial Interests, Personal, Financially compensated role: Radiomics. All other authors have declared no conflicts of interest.
Resources from the same session
175P - Radiomic biomarker of vessel tortuosity for monitoring treatment change: Preliminary findings in prospective evaluation of ECOG-ACRIN EA5163
Presenter: Pushkar Mutha
Session: Poster session 01
176P - Enhancing immunotherapy response prediction via multimodal integration of radiology and pathology deep learning models
Presenter: Marta Ligero
Session: Poster session 01
177P - Revealing differences in radiosensitivity of advanced non-small cell lung cancer (NSCLC)through single-cell sequencing data
Presenter: Peimeng You
Session: Poster session 01
178P - Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients
Presenter: Leonardo Provenzano
Session: Poster session 01
179P - Molecular tumor board directed treatment for patients with advanced stage solid tumors: A case-control study
Presenter: Dhruv Bansal
Session: Poster session 01
180P - An HLA-diet-oriented system unveiling organ-specific occurrence of multiple primary cancers (MPC) with prevention strategy: A large cohort study of 47,550 cancer patients
Presenter: Zixuan Rong
Session: Poster session 01
181P - GeNeo: Agnostic comprehensive genomic profiling versus limited panel organ-directed next-generation sequencing within the Belgian PRECISION initiative
Presenter: Philippe Aftimos
Session: Poster session 01
182P - ALK fusion detection by RNA next-generation sequencing (NGS) compared to DNA in a large, real-world non-small cell lung cancer (NSCLC) dataset
Presenter: Wade Iams
Session: Poster session 01
183P - Frequency of actionable fusions in 7,735 patients with solid tumors
Presenter: Kevin McDonnell
Session: Poster session 01
184P - Patient-specific HLA-I genotypes predict response to immune checkpoint blockade
Presenter: Kyrillus Shohdy
Session: Poster session 01